Vertical Longevity Pharmaceuticals is developing a vaccine platform designed to help the immune system recognize and clear senescent cells associated with aging and chronic disease. Its lead candidate, VLP-1, uses virus-like particle technology to direct that immune response, with an initial research focus on atherosclerosis, the buildup of plaque in arteries.
The company’s broader development plan explores whether the approach could be applied to additional age-related conditions. VLP-1 remains in preclinical development, with research focused on establishing the evidence needed to advance its safety, effectiveness, and eventual clinical evaluation.
Directive 17